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Decay-accelerating factor (DAF)' is a 70,000-Mr membrane protein that reg-
ulates the C3 and C5 convertases ofthe classical and alternative pathways (1-5).
It is amembrane constituent ofnormal human erythrocytes (Eh")(3), neutrophils,
lymphocytes, monocytes, platelets (6, 7), and endothelial cells (8), in which it is
anchored by a glycolipid involving phosphatidylinositol (9). It is considered that
DAFprotects host cells from damage by autologous complement. DAF is partially
or completely deficient in the membranes of erythrocytes of patients with
paroxysmal nocturnal hemoglobinuria (PNH), an acquired hemolytic anemia
characterized by an unusual susceptibility of red cells to complement-mediated
lysis (4, 6, 10).
The precise mechanism by which DAF regulates complement C3 convertase
is not entirely clear. DAF was first considered to accelerate the spontaneous
decay of the classical and alternative C3 convertases (3, 4). Subsequently, it was
reported thatpurified DAF,reincorporated into erythrocyte membranes, formed
a complex with C4b and C3b deposited on the membrane, and inhibited the
assembly ofthe C3 convertases (5, 11). It was proposed that DAF competitively
inhibits the uptake of C2 or factor B (11). In the present study, we show that
DAF acts on C2a and Bb, but not on intact C2 and B, and dissociates them
rapidly from C4b and C3b, respectively, thereby preventing the assembly of the
C3 convertases.
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Materials and Methods
Buffers and Complement Components.
￿
Isotonic veronal-buffered saline with 2.5% dex-
trose, containing 0.1% gelatin, 0.5 mM MgC12, and 0.15 mM CaCl2 (DGVB) and veronal-
buffered saline, containing 0.1% gelatin and 0.01 M EDTA (EDTA-GVB), were used.
Guinea pig C1 and C2 (12), human C4 (13), C2 (14), C3 (15), B (16), and D (17) were
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'Abbreviations used in this paper:
￿
C-EDTA, guinea pig serum diluted with EDTA-GVB; DAF,
decay-accelerating factor; DGVB,isotonic veronal-buffered saline with dextrose, gelatin, M9Cl2, and
CaC12; EDTA-GVB, veronal-buffered saline with gelatin and EDTA; E''", human erythrocytes; p-
APMSF, p-amidinophenyl-methanesulfonyl fluoride hydrochloride; PNH, paroxysmal nocturnal
hemoglobinuria.
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purified as described previously. Guinea pig serum diluted 1 :50 in EDTA-GVB (C-EDTA)
was used as a source of C3-C9.
Cellular Intermediates.
￿
Antibody-sensitized sheep erythrocytes carrying guinea pig C1
and human C4 (EAC14b) were prepared as described (18). EAC4b were prepared by
incubating EAC14b at 37°C for 30 min in EDTA-GVB and then treating them with 50
yM p-amidinophenyl-methanesulfonyl fluoride hydrochloride (p-APMSF; Wako Pure
Chemicals Industries, Ltd., Osaka, Japan) to destroy the remaining Cl . EAC4b3b cells
were prepared as follows: EAC14b (10'/ml) were incubated for 30 min at 37°C with 50
U/ml of guinea pig C2 and 300 U/ml of C3, and after washing, the cells were further
incubated at 37°C for 3 h . Purified DAF (20 Ag/ml) was incorporated into EAC14b,
EAC4b, and EAC4b3b cells (109/ml) by incubating at 37°C for 1 h. These cells,
ED^EAC14b, E°^EAC4b, and E°^FAC4b3b were washed three times with DGVB.
EAC14b2a were prepared by adding oxidized human C2 (19) to EAC14b to yield 1-1 .5
hemolytic sites per cell. Human erythrocytes (E''") were obtained from healthy donors and
sensitized with rabbit hemolysin (Cappel Laboratories, Cochranville, PA) in a subagglutin-
ating concentration. Et'"AC4b cells were prepared by the same methods as EAC4b cells.
Assay.
￿
The activity of isolated DAF or DAF-containing preparations was assayed by
its ability to accelerate the decay of EAC14b2a as originally described by Nicholson-
Weller et al . (3). Briefly, the sample was mixed with 10' EAC14b2a in a total volume of
0.3 ml, and incubated for 30 min at 30 °C. The residual hemolytic sites were developed
by adding 1 .2 ml of C-EDTA, followed by further incubation at 37°C for 1 h. Additional
details of the assay are given in the legends to the Figures.
Purification ofDAF.
￿
DAF was purified from pooled human erythrocyte stroma by the
method described by Nicholson-Weller et al. (3, 10) with modifications. Since we obtained
the mAbs to DAY, the fractions that showed DAY activity after anion-exchange column
were subjected to an affinity chromatography of monoclonal anti-DAF-coupled Sepharose
and
￿
eluted
￿
with
￿
3
￿
M
￿
KSCN,
￿
containing
￿
0.1 %
￿
Chaps
￿
(3-[(3-cholamidopropyl)-
dimethylammonio]-1-propanesulfonate; Dcjindo Laboratories, Kumamoto, Japan). To
remove the minor contaminants, we used reverse-phase HPLC through the TSK Phenyl
5PW-RP matrix (Toyosoda Manufacturing Co., Ltd., Tokyo, Japan). The main peak
contained only DAY protein as evaluated by SDS-PAGE and silver staining. The protein
concentration was calculated from its optical density at 280 nm, under the assumption
that an absorption coefficient value of 1 .0 equals 1 mg/ml.
mAbs to DAF.
￿
BALB/c mice were immunized twice with 5,ug of purified DAF in CFA.
3 wk later, the mice were boosted with 5 ug of DAY; the spleen was removed 3 d later
and used for fusion with myeloma cells (NS-1). Culture supernatants of the resulting
hybridoma were tested for anti-DAF activity as described previously (6) by immunoelec-
troblotting using an ABC kit (Vector Laboratories, Inc., Burlingame, CA) according to
the instructions of the manufacturer. As the positive control, we used rabbit anti-DAF
antibodies kindly supplied by Dr. V. Nussenzweig (New York University Medical Center,
New York). Four positive mAbs were obtained and purified to homogeneity from ascites
fluids of mice bearing the hybridoma by ammonium sulfate precipitation, followed by
chromatography on DEAE Toyopearl (Toyosoda Manufacturing Co., Ltd.). All antibodies
used in this study belonged to IgG1 K isotype.
Of the four mAbs (1 C6, 4F11, 5132, and 6F 10), I C6, 4F11, and 5112 recognized the
different epitopes on the DAY molecules, while 5112 and 6F10 recognized the same or
overlapping epitopes. I C6 alone completely inhibited DAF activity, and although the
other mAbs also inhibited DAF activity, their effects were weaker than that of 1C6.
However, these mAbs alone and any combination of these antibodies did not inhibit the
incorporation of radiolabeled DAY into sheep erythrocytes, showing that 1C6 is directed
to the active site on DAY molecule, not to the site that is anchored to the cell membrane
by phosphatidylinositol. In this study we used 1C6 to block the activity of DAF.
Radiolabeling. C2 was labeled with "'I in the presence of iodoacetamide-treated
monomeric human albumin (20) by using Iodogen (Pierce Chemical Co., Rockford, IL),
and unbound "'I was removed by gel filtration through Sephadex G-25 (Pharmacia Fine
Chemicals, Piscataway, NJ), followed by extensive dialysis. Since the hemolytic activityFUJITA ET AL .
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FIGURE 1 . The effect of
DAF on the decay and the
structure of C2 . EAC4b2 and
E°^FAC4b2 cells (10 8/ml)
were prepared by incubating
at 30°C for 15 min with
1251-
C2 (2.5 ug/ml), followed by
washing. The cells were resus-
pended in 1 ml of DGVB and
received 300 U of C1 . At
timed intervals, 100 ul ofsam-
ples were removed from each
tube and the reaction was
stopped by adding 2 uI of 5
mM p-APMSF . After centri-
fugation, 80 A1 ofsupernatants
were removed. The cells were
washed once with DGVB and
solubilized with 100 Wl of re-
ducing sample buffer . The su
pernatants and the solubilized cells were counted for radioactivity and analyzed by SDS-PAGE and
radioautography . From the radioactivities, the amounts of C2 bound toEAC4b2 (" ) and E°^EAC4b2
(/) cells were calculated and expressed as the percentage of the total counts (left) .The radioautographs
of EAC4b2 (A) and E°^EAC4b2 (B) are shown in the right panel .
was fully preserved, we used '251-C2 without further purification . FactorB was also labeled
with
'251 by using lodogen .
Structural Analysis ofRadiolabeled C2 and B .
￿
SDS-PAGE was performed according to
Laemmli (21) . After electrophoresis the gels were dried and analyzed by radioautography .
Results
Effect ofDAF on the Classical Pathway C3 Convertase.
￿
To study the effect of
DAF on the classical pathway C3 convertase, we prepared EAC4b2 and
ED"FAC4b2 cells with 1251-C2 . The same amounts of '251-C2 bound to EAC4b
and ED"EAC4b cells . After these cells received C 1, the mixtures were incubated
at 30'C and the samples were removed from each tube at time intervals to
measure the radioactivity and to analyze the C2 structure by SDS-PAGE and
radioautography . As seen in Fig . 1, the radioactivity of C2 dissociated more
rapidly from E°"FAC4b2a cells than from EAC4b2a cells . The rates of cleavage
of the bound 1251-C2 by C1 in both cells were the same . The C2b portion was
not well labeled with
1251 . In EAC4b2 cells, C2a gradually dissociated into the
supernatants, whereas in the DAF-treated cells, a large amount ofconverted
1251-
C2a rapidly appeared in the supernatants and only a small amount of C2a
remained on the cells . It is clear that DAF does not prevent the binding of C2
zymogen to Cob, but acts on C2a to dissociate it from the binding site of C4b .
A similar experiment was performed using human red cells . Eh°AC4b cells
were used as the cells having DAF, and Eh°AC4b pretreated with anti-DAF mAb
IC6 were used as the cells containing no DAF . As shown in Fig . 2, DAF on
human erythrocyte membranes also dissociated the C2a from the cells, and the
DAF activity was completely blocked by IC6 (Fig . 2) . The decay of C2a and its
radioautograph in 1C6-treated Eh°AC4b2 and Eh°AC4b2 (Fig . 2) are comparable
to those in EAC4b2 and E°AFAC4b2 (Fig . 1), respectively . Under physiologic
conditions, activated Cl, which is present in the vicinity of C4b, cleaved C21224 MECHANISM OF ACTION OF
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TABLE I
Binding ofC2 to DAF-incorporated EAC14b Cells
FIGURE 2 . Activity of DAF
on human erythrocyte mem-
branes . E''"AC4b cells (108/ml)
were treated at 0°C for 30
min with 1C6 (100 lug/ml) or
buffer . The cells were washed
and reacted with ""I-C2 (2 .5
lug/ml) at 30°C for 15 min .
Thesame radioactivities were
bound to E"AC4b and 1 C6-
treated E""AC4b cells . The
decay of C2 and its structural
change were analyzed by the
same procedures as described
in the legend of Fig. 1 . C2 on
Eh'AC46 (p) decayed more
rapidly than that on IC6-
treated Eh"AC4b (p) (left) . As
shown in A of the right panel,
only a small amount of C2a
wasobserved on E''"AC4b cells
at any time, while most ofC2a
appeared in the supernatants .
(B) C2a on 1C6-treated E''"-
AC4b decayed gradually and
appeared in the supernatants .
Number of C4b2a
sites
FAC4b and E°"FAC4b cells were reacted for 15 min at 30°C with a
limiting amount of oxidized C2 . After centrifugation, 100 lul of
E°^FAC4b2 cells (108/ml) were reacted with 100 Al of varyingamounts of
1C6 or buffer, and EAC4b2 cells were also reacted with buffer . After
washing, the cells were incubated with 100 Al of C1 (1,000 U/ml) at 30°C
for 15 min, and then further incubated with 1 .2 ml of C-EDTA to
quantitate the number of C4b2a sites .
bound to C4b into C2a and C2b. Simultaneously, DAF dissociates the generated
C2a from C4b, thereby preventing the assembly of the classical pathway C3
convertase, C4b2a.
C2 Depletion by E' "FAC14b .
￿
To confirm the above results, we determined
whether thehemolytically activeC2 binds to the DAF-incorporated cells . FAC4b
and E°AFAC4b cells were reacted with a limiting amount of oxidized C2 . DAF-
incorporated cells were incubated at 30°C for 30 min with different amounts of
IC6 . After adding Cl to the cells, the hemolytic activity ofC4b2a was assessed
(Table 1) . No hemolysis was observed in the DAF-incorporated EAC4b2a cells .
However, treatment with anti-DAF mAb restored the C4b2a hemolytic activity
on the DAF-incorporated cells, showing that hemolytically active C2 bound to
the DAF-treated C4b sites. In addition, we hemolytically measured C2 depletion
E°^FAC4b/buffer/C 1 0.03
E°"FAC4b2/1C6 (50 lug/ml)/C1 2.00
E°^FAC4b2/1C6 (10 lug/ml)/C1 1 .74
E°^FAC4b2/1C6 (2 ,ug/ml)/C1 1 .00
EAC462/buffer/C1 2.28100
50
3 6 10 15
￿
30
Time (min)
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FIGURE 3 . Depletion of C2 by EAC14b and
E°"FAC14b cells . EAC 1 (0), EAC14b (/) and
E°"FAC14b (A) cells (108/ml) were incubated at 30°C
with 6,000 U/ml of oxidized C2 for varying periods
of time and then the remainingC2 hemolytic activity
was assayed . ED"FAC14b consumed C2 more rapidly
than EAC14b . There is a small amount of C2 utiliza-
tion by EAC 1 cells .
FIGURE 4 .
￿
The effect ofDAF on the alternative
pathway C3 convertase, C3bBb . EAC4b3bB and
ED"FAC4b3bB cells (108/ml) were prepared by in-
cubation at 30°C for 15 min with . ..I-B (1 .5
,ug/ml). After washing, I ml of these cells received
3.2 ng of factor D, and the mixtures were incu-
bated at 30°C . At timed intervals, 100,u] ofsample
were removed from each tube and analyzed by
SDS-PAGE and radioautography . As shown in A,
in EAC4b3b cells, at 1 min, factorBwasconverted
to Bb and Ba by the action of factor D, and Bb
fragment remained on the cells, while Ba was ob-
served in the supernatants . TheboundBbdecayed
gradually and appeared in the supernatants . In B,
no Bb fragment wasobserved onE°"FAC4b3b cells
at any time, showing that DAF dissociates the Bb
from the cells .
from the fluid phase by EAC14b and EDAFACI4b cells. As shown in Fig . 3,
compared with the moderate depletion ofC2 by EAC14b, the rate of depletion
ofC2 by ED^FACI4b was more rapid . These results indicate that the accelerated
decay of C2a results in the rapid turnover of C2 on the DAF-incorporated
EAC14b cells .
Effect ofDAF on the Alternative Pathway C3 Convertase.
￿
Next, we investigated
whether DAF acts on thealternative pathway C3 convertase, C3bBb, in the same
manner . EAC4b3bB and ED"FAC4b3bB cells were prepared with I25I-B . Factor
D was added to these cellsand the mixtures were incubated at 30°C . The samples
were removed from each tube at time intervals and analyzed by SDS-PAGE and
radioautography (Fig . 4) . At 1 min most of 1251-B bound to EAC4b3b cells was
converted to Bb and Ba by the action of D. Bb remained bound to the cells,
while Ba appeared in the supernatant . The Bb decayed gradually and at 15 min
most of Bb dissociated from the cells. In the DAF-incorporated cells, on the1226
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other hand, Bb was not observed on the cells even at 1 min, although the same
amount of B was bound to the cells. These results clearly show that in the
alternative pathway intact B binds to C3b, and that DAF functions to release the
Bb generated by D.
Discussion
DAF was first reported to accelerate the decay-dissociation of C2a and Bb
from C4b2a and C3bBb, respectively (3, 4). Subsequently it was found that DAF
exhibits the unique property of being able to reassociate with red cells and
express its biological activity (5). It forms complexes with C4b and C3b deposited
on the erythrocytes (11), and inhibits the formation ofthe C3 convertase ofboth
the classical (C4b2a) and alternative (C3bBb) pathways (5). However, the precise
mode of action of DAF is not fully understood. In this study, we demonstrated
that DAF on the membranes of erythrocyte does not prevent the binding ofC2
and factor B zymogens to C4b and C3b, respectively, but dissociates C2a and Bb
from each binding site.
A key finding is that the same amount of the native C2 binds to C4b in the
presence and absence of DAF, whereas C2a cannot remain on DAF-treated C4b
sites (Figs. 1 and 2). These results were confirmed by the hemolytic assay (Table
I). Therefore, it is possible that DAF competitively inhibits the binding of C2a
generated by the action of Cls. Another possibility is that C4b molecule,
allosterically modified by the binding of DAF, cannot hold the C2a molecule
through the labile binding site. The latter possibility is more likely, because a
limiting amount of DAF within cell membranes accelerated the natural decay of
C2a (data not shown) and a small amount of C2a was observed on the cell
membranes even in the presence of a large excess of DAF (Figs. 1 and 2).
Whatever the mechanism, under physiologic conditions, DAF inhibits the assem-
bly ofthe C4b2aenzyme bydissociating the C2a (Fig. 2). The alternative pathway
C3 convertase, C3bBb, is regulated by DAF in the same manner (Fig. 4).
Recently, the molecular cloning of human DAF revealed that the deduced
DAF sequence contains four repeating units homologous to a consensus repeat
found in the complement proteins, factor B, C2, factor H, C4-binding protein,
CR1, and Clr (22, 23). These complement components areall C3b-and/or C4b-
bindingproteins as is DAF. Each recognizes the activation-dependent sites in the
structurally homologous C3b and C4b molecules, which deposit in clusters on
targets. It is likely that the repeating units serveasthe C3b/C4b-bindingdomains
of DAF and these other molecules. The binding site of 1C6 is close to the active
site of DAF molecule, not to the site that is anchored to the cell membrane by
phosphatidylinositol (9). In this respect, it is possible that 1C6 recognizes the
repeating unitsofDAF, thereby inhibiting theinteraction ofDAF with C3b/C4b.
In addition, our findings suggest that the whole molecule of C2 and its
fragment C2a bind to different sites of the C4b molecules (Figs. 1 and 2). The
previous reports show that the interaction ofCob and C2 appears to be mediated
by the C2b part of the C2 molecule (14). Taken together, it is likely that the
C2b region plays a role in the initial binding ofC2 to C4b, and after the cleavage
of C2 by Cls, the generated C2a binds to a different binding site on C4b
molecule, resulting in the generation ofproteolytic activity. This binding is labile
and affected by DAF. Similarly, our results (Fig. 4) are consistent with the recentreport (24) that a binding site for Cab on intact B is located on the Ba portion
of the molecule.
Summary
DAF is a 70,000-M, membrane protein that inhibits the amplification of the
complement cascade on the cell surface, and protects cells from damage by
complement. The precise mechanism of action of DAF is not entirely clear.
Purified DAF was incorporated into the membrane of EAC4b cells. EAC4b2
and EDAFAC4b2 cells were prepared with radiolabeled C2 . The same amount of
labeled C2 bound to both cells, showing that DAF does not prevent the binding
of C2 zymogen to C4b. After adding Cl, the radioactivity of bound C2 disso-
ciated more rapidly from EDAFAC4b cells than from EAC4b cells. In EAC4b
cells, bound C2 was converted to C2a, which gradually dissociated into the
supernatants. In the DAF-treated cells, on the other hand, a large amount of
C2a rapidly appeared in the supernatants and only a small amount of C2a
remained on the cells. In a similar experiment using E"°AC4b, DAF on human
erythrocyte membrane also dissociated the C2a from the cells. These results
were confirmed by hemolytic assay and the accelerated decay of C2a caused the
rapid depletion of C2 from the fluid phase. In addition, we found that DAF
functions on the alternative pathway C3 convertase, C3bBb in the same manner.
Thus, DAF, which associates with C4b and C3b in the membrane, acts on C2a
and Bb, but not on intact C2 and B, and dissociates them rapidly from the
binding sites, thereby preventing the assembly of the classical and alternative
pathways C3 convertases.
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